BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS SOPH , a cloud-native healthcare technology company and global leader in...
Daiichi Sankyo Competitors or Alternatives
Daiichi Sankyo's top competitors include AstraZeneca, Bristol-Myers Squibb and Altor BioScience.
Daiichi Sankyo VS AstraZeneca
AstraZeneca is one of Daiichi Sankyo's top competitors. AstraZeneca is a Public company that was founded in Cambridge, England in 1999. AstraZeneca is in the Pharmaceuticals field. AstraZeneca has 71,174 more employees vs. Daiichi Sankyo.
Daiichi Sankyo VS Bristol-Myers Squibb
Bristol-Myers Squibb is perceived as one of Daiichi Sankyo's biggest rivals. Bristol-Myers Squibb was founded in 1858 in Princeton, New Jersey. Bristol-Myers Squibb competes in the Pharmaceuticals industry. Bristol-Myers Squibb generates $36.1B more revenue than Daiichi Sankyo.
Looking for similar companies to Daiichi Sankyo?
Similar Companies
Pharmaceuticals & Biotechnology companies in Chuo-ku
See 10 companies
Companies in Chuo-ku with revenue in $10-50B rangeSee 11 companies
Pharmaceuticals companies with revenue in $10-50B rangeSee 32 companies
Companies in Chuo-ku with employees in 10-50K rangeSee 14 companies
Pharmaceuticals & Biotechnology companies with revenue in $10-50B rangeSee 40 companies
Pharmaceuticals companies in Tōkyō PrefectureSee 45 companies
Pharmaceuticals & Biotechnology companies in Tōkyō PrefectureSee 71 companies
Pharmaceuticals companies with employees in 10-50K rangeSee 76 companies
Companies in Tōkyō Prefecture with revenue in $10-50B rangeSee 106 companies
Trending News for Daiichi Sankyo and Daiichi Sankyo's Competitors
Daiichi Sankyo has reiterated that its earlier plans to expand ADC manufacturing in the US, including for its blockbuster drug Enhertu, will help allev...
In This Article: ADC Therapeutics SA (ADCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for...
The Bayer Group made major progress in a number of areas in 2024 and is actively taking steps to tackle the serious challenges it faces. "We're working...
Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025 (Korea Bizwire) New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and...
In the pivotal CREST clinical trial, sasanlimab in combination with Bacillus Calmette-Guérin met the primary endpoint of event-free survival....
Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs....
Merck, known as MSD outside of the United States and Canada, announced results from the phase 3 KEYNOTE─689 trial evaluating Keytruda (pembrolizumab), ...
The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for Tepezza (teprotumumab), for the t...
(RTTNews) - Johnson & Johnson (JNJ)today announced new data from Cohort 2 of the pivotal Phase 2b SunRISe-1 study evaluating TAR-200-an intravesical ge...
Frequently Asked Questions about Daiichi Sankyo
Who are Daiichi Sankyo's top competitors?
Daiichi Sankyo's top 3 competitors are AstraZeneca, Bristol-Myers Squibb, Altor BioScience.Who is similar to Daiichi Sankyo?
AstraZeneca is the most similar to Daiichi Sankyo. Bristol-Myers Squibb and Altor BioScience are also similar to Daiichi Sankyo.
Are Daiichi Sankyo and AstraZeneca competitors?
Yes, AstraZeneca is one of Daiichi Sankyo’s top competitors.